Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity
Asia Pacific pharmaceutical manufacturing industry market will grow by 11.3% annually with a total addressable market cap of $57.26 billion over 2023-2032. The growth is driven by the increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high R&D investment in pharmaceutical industry, increasing per capita healthcare expenditure, and technological advancements in manufacturing processes.
Highlighted with 90 tables and 69 figures, this 168-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry market in every aspect of the classification from perspectives of Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.
Based on Formulation, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Oral Medicine
• Topical Medicine
• Parenteral Medicine
• Inhalations
• Other Routes of Administration
By Consumer Group, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Children & Adolescents (17 years old and below)
• Adults (18-64 years old)
• Geriatric (65 years old and above)
By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Neurological Diseases
• Orthopedics
• Other Applications
By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
By Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Retail Channels
• Non-retail Channels
By Manufacturing Facility, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• In-house Facility
• Outsourced Facility
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Formulation, Route of Administration, and Drug Type over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Aenova Group
Amgen Inc.
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin Limited
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Patheon Inc.
Pfizer CentreSource
Sanofi SA
Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the Market 27
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 29
2.2 Major Growth Drivers 33
2.3 Market Restraints and Challenges 40
2.4 Emerging Opportunities and Market Trends 43
2.5 Porter’s Fiver Forces Analysis 47
3 Segmentation of Asia Pacific Market by Formulation 51
3.1 Market Overview by Formulation 51
3.2 Tablets 53
3.3 Capsules 54
3.4 Injectable 55
3.5 Sprays 56
3.6 Suspensions 57
3.7 Powders 58
3.8 Other Formulations 59
4 Segmentation of Asia Pacific Market by Route of Administration 60
4.1 Market Overview by Route of Administration 60
4.2 Oral Medicine 62
4.3 Topical Medicine 63
4.4 Parenteral Medicine 64
4.5 Inhalations 65
4.6 Other Routes of Administration 66
5 Segmentation of Asia Pacific Market by Consumer Group 67
5.1 Market Overview by Consumer Group 67
5.2 Children & Adolescents (17 years old and below) 69
5.3 Adults (18-64 years old) 70
5.4 Geriatric (65 years old and above) 71
6 Segmentation of Asia Pacific Market by Therapeutic Application 72
6.1 Market Overview by Therapeutic Application 72
6.2 Cardiovascular Diseases 74
6.3 Pain 75
6.4 Diabetes 76
6.5 Cancer 77
6.6 Respiratory Diseases 78
6.7 Neurological Diseases 79
6.8 Orthopedics 80
6.9 Other Applications 81
7 Segmentation of Asia Pacific Market by Drug Type 82
7.1 Market Overview by Drug Type 82
7.2 Branded Prescription Drugs 84
7.3 Generic Prescription Drugs 85
7.4 OTC Drugs 86
8 Segmentation of Asia Pacific Market by Distribution Channel 87
8.1 Market Overview by Distribution Channel 87
8.2 Retail Channels 89
8.3 Non-retail Channels 90
9 Segmentation of Asia Pacific Market by Manufacturing Facility 91
9.1 Market Overview by Manufacturing Facility 91
9.2 In-house Facility 93
9.3 Outsourced Facility 94
10 Asia-Pacific Market 2022-2032 by Country 95
10.1 Overview of Asia-Pacific Market 95
10.2 Japan 99
10.3 China 102
10.4 Australia 104
10.5 India 107
10.6 South Korea 109
10.7 Rest of APAC Region 111
11 Competitive Landscape 113
11.1 Overview of Key Vendors 113
11.2 New Product Launch, Partnership, Investment, and M&A 116
11.3 Company Profiles 117
Abbott Laboratories 117
Aenova Group 119
Amgen Inc. 123
AstraZeneca 126
Catalent Inc. 129
Eli Lilly and Company 132
F. Hoffmann-La Roche Ltd. 134
Gilead Sciences Inc. 136
GlaxoSmithKline plc 138
Johnson & Johnson 142
Lonza Group 144
Lupin Limited 147
Merck & Co., Inc. 149
Novartis AG 151
Novo Nordisk 153
Patheon Inc. 156
Pfizer CentreSource 160
Sanofi SA 164
Takeda 166
RELATED REPORTS 168
List of Tables:
Table 1. Snapshot of Asia Pacific Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032 19
Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change 23
Table 3. World Economic Outlook, 2021-2031 25
Table 4. World Economic Outlook, 2021-2023 26
Table 5. Scenarios for Economic Impact of Ukraine Crisis 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 39
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Manufacturing Industry 43
Table 8. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 51
Table 9. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 60
Table 10. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, $ mn 67
Table 11. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, $ mn 72
Table 12. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 82
Table 13. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, $ mn 87
Table 14. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, $ mn 91
Table 15. APAC Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn 97
Table 16. Japan Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 101
Table 17. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 101
Table 18. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 101
Table 19. China Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 103
Table 20. China Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 103
Table 21. China Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 103
Table 22. Australia Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 106
Table 23. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 106
Table 24. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 106
Table 25. India Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 108
Table 26. India Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 108
Table 27. India Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 108
Table 28. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn 110
Table 29. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn 110
Table 30. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn 110
Table 31. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2022-2032, $ mn 112
Table 32. Abbott Laboratories: Company Snapshot 117
Table 33. Abbott Laboratories: Business Segmentation 118
Table 34. Abbott Laboratories: Product Portfolio 118
Table 35. Aenova Group: Company Snapshot 119
Table 36. Aenova Group: Business Segmentation 120
Table 37. Aenova Group: Revenue by Product, 2018-2019, thousand Euro 121
Table 38. Aenova Group: Recent Developments 122
Table 39. Amgen Inc.: Company Snapshot 123
Table 40. Amgen Inc.: Approved Drugs or Therapeutic Biologicals 124
Table 41. Astrazeneca: Company Snapshot 126
Table 42. Catalent Inc.: Company Snapshot 129
Table 43. Catalent Inc.: Business Segmentation in 2018 130
Table 44. Catalent Inc.: Product Portfolio 130
Table 45. Catalent Inc.: Revenue, 2018-2020, $ million 131
Table 46. Catalent Inc.: Revenue by Region in 2018 131
Table 47. Eli Lilly and Company: Company Snapshot 132
Table 48. Eli Lilly and Company: Pharmaceutical Brands 133
Table 49. F. Hoffmann-La Roche: Company Snapshot 134
Table 50. F. Hoffmann-La Roche: Business Segmentation 134
Table 51. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 135
Table 52. Gilead Sciences: Company Snapshot 136
Table 53. Gilead Sciences: Main Products 136
Table 54. GlaxoSmithKline: Company Snapshot 138
Table 55. GlaxoSmithKline: Business Segmentation 139
Table 56. GlaxoSmithKline: Product Portfolio 140
Table 57. GlaxoSmithKline: Revenue, 2018-2020, $ bn 141
Table 58. Johnson & Johnson: Company Snapshot 142
Table 59. Johnson & Johnson: Business Segments 142
Table 60. Lonza Group: Company Snapshot 144
Table 61. Lonza Group: Business Segmentation in 2018 144
Table 62. Lonza Group: Product Portfolio 145
Table 63. Lonza Group: Revenue by Region in 2018 145
Table 64. Lupin Limited: Company Snapshot 147
Table 65. Lupin Limited: Business Segmentation 148
Table 66. Merck & Co., Inc.: Company Snapshot 149
Table 67. Merck & Co., Inc.: Business Segmentation 149
Table 68. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 150
Table 69. Novartis International AG: Company Snapshot 151
Table 70. Novartis International AG: Business Segmentation 151
Table 71. Novartis International AG: Revenue, 2017-2019, $ bn 152
Table 72. Novo Nordisk: Company Snapshot 153
Table 73. Novo Nordisk: Product Portfolio 154
Table 74. Patheon Inc.: Company Snapshot 156
Table 75. Patheon Inc.: Business Segmentation in 2018 157
Table 76. Patheon Inc.: Product Portfolio 157
Table 77. Patheon Inc.: Revenue, 2017-2019, $ billion 158
Table 78. Patheon Inc.: Revenue by Region in 2018 158
Table 79. Patheon Inc.: Recent Developments 159
Table 80. Pfizer CentreSource: Company Snapshot 160
Table 81. Pfizer CentreSource: Business Segmentation in 2018 161
Table 82. Pfizer CentreSource: Product Portfolio 161
Table 83. Pfizer CentreSource: Revenue, 2017-2019, $ billion 162
Table 84. Pfizer CentreSource: Revenue by Region in 2018 162
Table 85. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot 162
Table 86. Pfizer CentreSource: Recent Developments 163
Table 87. Sanofi: Company Snapshot 164
Table 88. Sanofi: Business Segmentation 164
Table 89. Sanofi: Revenue, 2018-2020, $ bn 165
Table 90. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 166
List of Figures:
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 18
Figure 4. Asia Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 21
Figure 5. World Healthcare Services Production, annual percentage change 23
Figure 6. Impact of COVID-19 on Business 27
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 33
Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century 36
Figure 9. Leading Causes of Death in the World, 2000 and 2019, million 37
Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 38
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 38
Figure 12. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 40
Figure 13. Investment Opportunity Analysis 44
Figure 14. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry 47
Figure 15. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue 52
Figure 16. Asia Pacific Addressable Market Cap in 2023-2032 by Formulation, Value ($ mn) and Share (%) 52
Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, $ mn 53
Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, $ mn 54
Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, $ mn 55
Figure 20. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, $ mn 56
Figure 21. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, $ mn 57
Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Powders, 2022-2032, $ mn 58
Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, $ mn 59
Figure 24. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue 61
Figure 25. Asia Pacific Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%) 61
Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, $ mn 62
Figure 27. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, $ mn 63
Figure 28. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, $ mn 64
Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, $ mn 65
Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, $ mn 66
Figure 31. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue 68
Figure 32. Asia Pacific Addressable Market Cap in 2023-2032 by Consumer Group, Value ($ mn) and Share (%) 68
Figure 33. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, $ mn 69
Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, $ mn 70
Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, $ mn 71
Figure 36. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue 73
Figure 37. Asia Pacific Addressable Market Cap in 2023-2032 by Therapeutic Application, Value ($ mn) and Share (%) 73
Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, $ mn 74
Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, $ mn 75
Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, $ mn 76
Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, $ mn 77
Figure 42. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, $ mn 78
Figure 43. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, $ mn 79
Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, $ mn 80
Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, $ mn 81
Figure 46. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue 83
Figure 47. Asia Pacific Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%) 83
Figure 48. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, $ mn 84
Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, $ mn 85
Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, $ mn 86
Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue 87
Figure 52. Asia Pacific Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%) 88
Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, $ mn 89
Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, $ mn 90
Figure 55. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue 91
Figure 56. Asia Pacific Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value ($ mn) and Share (%) 92
Figure 57. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, $ mn 93
Figure 58. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, $ mn 94
Figure 59. Asia-Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn 96
Figure 60. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue 96
Figure 61. Contribution to APAC 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 98
Figure 62. Pharmaceutical Manufacturing Industry in Japan, 2022-2032, $ mn 100
Figure 63. Pharmaceutical Manufacturing Industry in China, 2022-2032, $ mn 102
Figure 64. Pharmaceutical Manufacturing Industry in Australia, 2022-2032, $ mn 104
Figure 65. Pharmaceutical Manufacturing Industry in India, 2022-2032, $ mn 107
Figure 66. Pharmaceutical Manufacturing Industry in South Korea, 2022-2032, $ mn 109
Figure 67. Pharmaceutical Manufacturing Industry in Rest of APAC, 2022-2032, $ mn 111
Figure 68. Growth Stage of Asia Pacific 3D Printing Industry over the Forecast Period 113
Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 127
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|